In what Hyderabad-based Bharat Biotech claims is the largest efficacy trial in India across 25 trial sites, the company claims its Covid-19 vaccine Covaxin is 65 per cent effective against the Delta variant. In a pre-print paper that is yet to be peer-reviewed, the company claimed that the vaccine is also 63 per cent effective …
Covaxin 65% Effective Against Delta Variant, Phase 3 Study Reveals Read More »
As per the press release by PIB, Aarogya Setu has rolled out a feature to update Vaccination Status on the Aarogya Setu App. Here is the step wise explanation of how to update the vaccination status. How to update Vaccination status for SELF: Those who are fully Vaccinated will get a Blue Shield on the …
Aarogya Setu rolls out new feature to update Vaccination Status Read More »
Under Atma Nirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines. This is being implemented by the Department of Biotechnology, Govt. of India at Biotechnology Industry Research Assistance Council (BIRAC), New Delhi. To augment the capacity of Indigenous production of Covaxin …
The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021. …
DCGI approves Phase 2 and 3 clinical trial of COVAXIN in the age group of 2 to 18 Years Read More »
Bharat Biotech has announced the cost of COVAXIN for State governments and Private Hospitals. It will cost 600 rupees per dose for State Governments and 1200 rupees per dose for Private Hospitals. The price of vaccine for export is 15 to 20 dollars.
Interacting with the Chief Ministers of all states, Mr Modi took stock of COVID-19 situation and discussed vaccination roll out programme. He said, two vaccines Covishield and Covaxin, which are made in India, have been granted approval for emergency use. He said, both the vaccines are cost-effective.
DCGI clears Covid-19 vaccines Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for restricted use in emergency
India’s indigenous coronavirus vaccine, Covaxin, has shown to generate robust immune response in its first phase clinical trials. A detailed immunogenicity response of the first phase trials of the vaccine has been declared by the manufacturers. Covaxin, jointly developed by Hyderabad based Bharat Biotech and ICMR has been found to be safe generating no serious …